Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 4/20 | 0.45 |
| ▸ | P2RX2 | Q9UBL9 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | WDR5 | P61964 | 1/20 | 0.36 |
| ▸ | CTSA | P10619 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10242913 | 0.92 | WDR5 (0.40) | P2RX3P2RX2KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL10242882 | 0.90 | ALDH1A1 (0.41) | P2RX3P2RX2KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL10243237 | 0.87 | P2RX3 (0.46) | P2RX3P2RX2TSHRTP53F2 | |
| SCHEMBL10243307 | 0.86 | P2RX3 (0.48) | P2RX3P2RX2KDM4EL3MBTL1TSHR | |
| SCHEMBL10242940 | 0.85 | NPC1 (0.40) | P2RX3P2RX2KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL10242905 | 0.85 | KDM4E (0.42) | P2RX3P2RX2KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL10243077 | 0.84 | P2RX3 (0.48) | P2RX3P2RX2ALDH1A1TSHRCYP3A4 | |
| SCHEMBL10243102 | 0.84 | P2RX3 (0.50) | P2RX3P2RX2TSHRCYP3A4CYP2C9 | |
| SCHEMBL10243090 | 0.84 | P2RX3 (0.52) | P2RX3P2RX2KDM4EL3MBTL1CYP2C9 | |
| SCHEMBL10242922 | 0.84 | SMN1; SMN2 (0.44) | P2RX3P2RX2KDM4EALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10201525-B2 | Tetrazole-substituted arylamides as PX2 and PX2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2019-02-12 | — | — | US | disclosed |
| US-20170143672-A1 | TETRAZOLE-SUBSTITUTED ARYLAMIDES AS PX2 AND PX2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170143672-A1 | TETRAZOLE-SUBSTITUTED ARYLAMIDES AS PX2 AND PX2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2017-05-25 | — | — | US | disclosed |
| US-9593128-B2 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | HOFFMANN-LA ROCHE INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-9593128-B2 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | HOFFMANN-LA ROCHE INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-9512089-B2 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2016-12-06 | — | — | US | disclosed |
| US-9512089-B2 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2016-12-06 | — | — | US | disclosed |
| EP-2038264-B1 | TETRAZOLE-SUBSTITUTED ARYLAMIDES | HOFFMANN LA ROCHE (CH) | 2016-10-26 | — | — | EP | disclosed |
| EP-2592070-B1 | Tetrazole-substituted arylamides | HOFFMANN LA ROCHE (CH) | 2016-08-31 | — | — | EP | disclosed |
| US-20150191487-A1 | TETRAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | GENENTECH, INC. (US) | 2015-07-09 | — | — | US | disclosed |
| US-20090326220-A1 | Tetrazole-Substituted Arylamides as P2X3 and P2X2/3 Antagonists | DILLON MICHAEL PATRICK | 2009-12-31 | — | — | US | disclosed |
| US-20090326220-A1 | Tetrazole-Substituted Arylamides as P2X3 and P2X2/3 Antagonists | DILLON MICHAEL PATRICK | 2009-12-31 | — | — | US | disclosed |
| US-7595405-B2 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2009-09-29 | — | — | US | disclosed |
| US-7595405-B2 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2009-09-29 | — | — | US | disclosed |
| WO-2009077371-A1 | TETRAZOLE-SUBSTITUTED ARYLAMIDE DERIVATIVES AND THEIR USE AS P2X3 AND/OR P2X2/3 PURINERGIC RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | WO | disclosed |
| US-20090163502-A1 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC | 2009-06-25 | — | — | US | disclosed |
| US-20090163502-A1 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC | 2009-06-25 | — | — | US | disclosed |
| US-20080004442-A1 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC | 2008-01-03 | — | — | US | disclosed |
| US-20080004442-A1 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC | 2008-01-03 | — | — | US | disclosed |
| WO-2008000645-A1 | TETRAZOLE-SUBSTITUTED ARYLAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170143672-A1 | TETRAZOLE-SUBSTITUTED ARYLAMIDES AS PX2 AND PX2/3 ANTAGONISTS | P2RX2, P2RX3, TPX2 | P2RX3 2/4885P2RX2 1/4885KDM4E 3543/4885 |
| US-20090163502-A1 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | P2RX3, P2RX2, P2RX7 | P2RX3 1/4885P2RX2 2/4885KDM4E 3385/4885 |
| US-10201525-B2 | Tetrazole-substituted arylamides as PX2 and PX2/3 antagonists | P2RX2, P2RX3, TPX2 | P2RX3 2/4885P2RX2 1/4885KDM4E 3508/4885 |
| US-20150191487-A1 | TETRAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX2, P2RX5 | P2RX3 1/4885P2RX2 2/4885KDM4E 3644/4885 |
| US-20090326220-A1 | Tetrazole-Substituted Arylamides as P2X3 and P2X2/3 Antagonists | P2RX3, P2RX2, P2RX5 | P2RX3 1/4885P2RX2 2/4885KDM4E 3644/4885 |
| US-20080004442-A1 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | P2RX3, P2RX2, P2RX5 | P2RX3 1/4885P2RX2 2/4885KDM4E 3644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.